AI assistant
CSL Ltd. — Board/Management Information 2011
Mar 28, 2011
17854_rns_2011-03-28_7dd6c4b6-6bb7-4c63-896e-399491e61694.pdf
Board/Management Information
Open in viewerOpens in your device viewer
For immediate release 29 March 2011
==> picture [205 x 32] intentionally omitted <==
==> picture [59 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
CHANGES TO CSL SENIOR EXECUTIVE GROUP
CSL Limited (ASX:CSL) Australia’s leading biopharmaceutical company, today announced a change to its senior executive group.
Mr Peter Turner will hand over his responsibilities as President, CSL Behring to Mr Paul Perreault effective 1 July 2011.
Mr Perreault, is currently a member of the CSL Behring leadership team holding the position Executive Vice President, Commercial Operations. His career spans 30 years in the Pharmaceutical industry in sales, marketing, business development and operational roles with both a US and international focus.
Mr Turner will return to Australia later in the year. He will be available on a parttime basis to undertake a range of projects and will continue as an Executive Director.
Dr Brian McNamee, CEO and Managing Director of CSL acknowledged the contribution Mr Turner had made to the growth and success of the CSL Group. “Peter has been a great contributor to the success story of CSL and he leaves CSL Behring in excellent shape with a strong team, excellent growth prospects and a culture which emphasises delivery against challenging goals as well as strong values and ethics” he said today. “Paul represents continuity of our strategy in CSL Behring. He brings solid experience and strong leadership qualities to this role. I look forward to working closely with him.”
Miss Elizabeth Alexander, Chairman CSL Limited, in welcoming the opportunity to retain Mr Turner’s services as an Executive Director, said, “Over the past 40 years Peter has gained exceptional knowledge of the plasma industry which is extremely valuable to CSL and the Board. After contributing to the Company overseas for eleven years through leadership roles in Switzerland and the United States, we welcome him back to Melbourne. I am very pleased that we have been able to plan successfully to replace Peter in this important role and to have the benefit of his continuing contribution.”
==> picture [99 x 7] intentionally omitted <==
==> picture [59 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
Page 2
Miss Alexander added “Paul is well known to the Board. He has been a very effective global leader in Commercial Operations and we are confident he will smoothly take the reins of CSL Behring with the full support of an excellent and experienced team.”
Mr Perreault will be succeeded in his global Commercial Operations role by Dr Ingolf Sieper currently Vice President, Central Europe Commercial Operations.
For more information about CSL Limited, visit www.csl.com.au
Media Contacts
Sharon McHale Senior Director Public Affairs Phone: 61 3 9389 1506 Mobile: +61 409 978 314 Email: [email protected]
Investor Contact:
Mark Dehring Director of Investor Relations Phone: 61 3 9389 2818 Email: [email protected]
==> picture [99 x 7] intentionally omitted <==